“Passive transfer of antibodies from mothers to infants via breast milk is an innovative approach to potentially improve infection resistance in infants,” said $VXRT CMO Dr. Cummings. https://t.co/7MYdZlgjGE #pillthatmovestheneedle#norovirus#globalhealth
🚨Well, hells bells! As had been previously signaled in the clinical trials—here is confirmation of a statistically significant association between Pfizer’s RSV vaccine & preterm births!
Beware mommas! 🙏🏻
@ChildrensHD
https://t.co/XRLfhC9UNG
Promising Advancements in Norovirus Vaccine Development for Lactating Mothers: Antibody Elevation in Breast Milk: $VXRT for https://t.co/savSNU2v19 :In recent developments in vaccine research, Vaxart has announced… https://t.co/ELFUfqawxb #VXRT#VaxartInc#ClinicalStudy#News
$VXRT CMO Dr. Cummings: “This is an important step forward as we drive toward a vaccine candidate that may make it possible for mothers to protect their children against this highly contagious – and potentially lethal – virus.” https://t.co/7MYdZlgjGE #pillthatmovestheneedle
$VXRT today said it has completed the topline analysis for the Phase 1 clinical trial evaluating its oral pill bivalent norovirus vaccine candidate in lactating mothers. View the full release here: https://t.co/7MYdZlgjGE. #pillthatmovestheneedle#norovirus
$VXRT CSO Dr. Tucker: "Going forward, we plan to meet with the FDA during the second quarter of 2024 to discuss our data on potential correlates, a Phase 2b dose confirmation study and potentially a GII.4 challenge study." https://t.co/to5Z3sBBeO #pillthatmovestheneedle
$VXRT currently expects to announce topline results from the Phase 1 trial of its oral bivalent norovirus vaccine candidate in mid-2024, CSO Dr. Sean Tucker notes. https://t.co/O08ZBadjKM #pillthatmovestheneedle#norovirus#publichealth
$VXRT Chair Dr. Finney explains that new CEO Steve Lo brings a wealth of biopharma experience to Vaxart, with more than 25 years in healthcare, biotech and pharmaceuticals. https://t.co/810e9M5UHM #pillthatmovestheneedle#CEO#vaccines#globalhealth